{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "marketState": "PRE", "exchange": "NMS", "regularMarketChangePercent": 1.8442557, "regularMarketPrice": 9.94, "firstTradeDateMilliseconds": 1610116200000, "priceHint": 2, "earningsTimestamp": 1683835260, "earningsTimestampStart": 1691490600, "earningsTimestampEnd": 1692009000, "trailingAnnualDividendRate": 0.0, "trailingPE": 4.124481, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": 2.41, "epsForward": -3.17, "epsCurrentYear": -3.43, "priceEpsCurrentYear": -2.897959, "sharesOutstanding": 39343600, "bookValue": 11.683, "fiftyDayAverage": 10.3846, "fiftyDayAverageChange": -0.4446001, "fiftyDayAverageChangePercent": -0.04281341, "twoHundredDayAverage": 11.72145, "twoHundredDayAverageChange": -1.7814503, "twoHundredDayAverageChangePercent": -0.15198207, "marketCap": 391075360, "forwardPE": -3.1356466, "priceToBook": 0.85080886, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-01-08", "prevName": "Cullinan Management, Inc.", "nameChangeDate": "2023-05-15", "averageAnalystRating": "1.5 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "shortName": "Cullinan Oncology, Inc.", "longName": "Cullinan Oncology, Inc.", "messageBoardId": "finmb_539392639", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChange": 0.17999935, "regularMarketTime": 1684180804, "regularMarketDayHigh": 10.0, "regularMarketDayRange": "9.58 - 10.0", "regularMarketDayLow": 9.58, "regularMarketVolume": 156761, "regularMarketPreviousClose": 9.76, "bid": 0.0, "ask": 0.0, "bidSize": 8, "askSize": 8, "fullExchangeName": "NasdaqGS", "financialCurrency": "USD", "regularMarketOpen": 9.79, "averageDailyVolume3Month": 211950, "averageDailyVolume10Day": 191060, "fiftyTwoWeekLowChange": 2.1579995, "fiftyTwoWeekLowChangePercent": 0.27730653, "fiftyTwoWeekRange": "7.782 - 15.89", "fiftyTwoWeekHighChange": -5.950001, "fiftyTwoWeekHighChangePercent": -0.37444937, "fiftyTwoWeekLow": 7.782, "fiftyTwoWeekHigh": 15.89, "displayName": "Cullinan Oncology", "symbol": "CGEM"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "One Main Street", "address2": "Suite 1350", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "617 410 4650", "website": "https://www.cullinanoncology.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Cullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer. Its products also include CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors; and CLN-418, a human bispecific antibody that is in Phase 1 clinical trial for the treatment of solid tumors. In addition, the company's preclinical product includes CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 62, "companyOfficers": [{"maxAge": 1, "name": "Mr. Nadim  Ahmed", "age": 54, "title": "Pres, CEO & Director", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 1137777, "fmt": "1.14M", "longFmt": "1,137,777"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jeffrey  Trigilio", "age": 37, "title": "CFO & Treasurer", "yearBorn": 1985, "fiscalYear": 2022, "totalPay": {"raw": 727986, "fmt": "727.99k", "longFmt": "727,986"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 745313, "fmt": "745.31k", "longFmt": "745,313"}}, {"maxAge": 1, "name": "Dr. Patrick A. Baeuerle Ph.D.", "age": 64, "title": "Chief Scientific Officer", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": {"raw": 763734, "fmt": "763.73k", "longFmt": "763,734"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 3785044, "fmt": "3.79M", "longFmt": "3,785,044"}}, {"maxAge": 1, "name": "Ms. Jacquelyn L. Sumer J.D.", "age": 43, "title": "Chief Legal Officer, Chief Compliance Officer & Corp. Sec.", "yearBorn": 1979, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Rose  Weldon", "title": "Sr. VP of Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Steve  Andre", "title": "Chief HR Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Corinne  Savill Ph.D.", "age": 63, "title": "Chief Bus. Officer", "yearBorn": 1959, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jennifer  Michaelson Ph.D.", "age": 54, "title": "Chief Devel. Officer", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jeffrey  Jones M.B.A., M.D., M.P.H.", "age": 50, "title": "Chief Medical Officer", "yearBorn": 1972, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Kevin A. Johnston", "title": "Chief Technical Operations Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}